Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Incorporating Known Genetic Variants Does Not Improve the Accuracy of PSA Testing to Identify High Risk Prostate Cancer on Biopsy.

PloS one - 1 Jan 2015

Gilbert Rebecca, Martin Richard M, Evans David M, Tilling Kate, Davey Smith George, Kemp John P, Lane J Athene, Hamdy Freddie C, Neal David E, Donovan Jenny L, Metcalfe Chris

Abstract excerpt

INTRODUCTION: Prostate-specific antigen (PSA) testing is a widely accepted screening method for prostate cancer, but with low specificity at thresholds giving good sensitivity. Previous research identified four single nucleotide polymorphisms (SNPs) principally associated with circulating PSA levels rather than with prostate cancer risk (TERT rs2736098, FGFR2 rs10788160, TBX3 rs11067228, KLK3 rs17632542)....

Read the complete abstract on PubMed

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biopsy
Share to FGFR2 gene
Share to TERT gene
Share to Polymorphism, Single Nucleotide
Share to Prostate-Specific Antigen
Share to Prostatic Neoplasms
Share to Risk Factors
Share to Sensitivity and Specificity

Source

Open in PubMed Open full text

Identifiers

PMID: 26431041
DOI: 10.1371/journal.pone.0136735
PMCID: PMC4592274

Genes

FGFR2
KLK3
TBX3
TERT

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Incorporating Known Genetic Variants Does Not Improve the Accuracy of PSA Testing to Identify High Risk Prostate Cancer on Biopsy.PMID 26431041Read ↗

Impact of prostate-specific antigen on a baseline prostate cancer risk assessment including genetic risk.Semantic proximity Read ↗

A genetic score can identify men at high risk for prostate cancer among men with prostate-specific antigen of 1-3 ng/ml.Semantic proximity Read ↗

Combining 33 genetic variants with prostate-specific antigen for prediction of prostate cancer: longitudinal study.Semantic proximity Read ↗

Personalized prostate cancer screening: improving PSA tests with genomic information.Semantic proximity Read ↗

Association of reported prostate cancer risk alleles with PSA levels among men without a diagnosis of prostate cancer.Semantic proximity Read ↗

Prostate cancer risk variants are not associated with disease progression.Semantic proximity Read ↗

Genetic correction of PSA values using sequence variants associated with PSA levels.Semantic proximity Read ↗

Plateau effect of prostate cancer risk-associated SNPs in discriminating prostate biopsy outcomes.Semantic proximity Read ↗

An analysis of the association between prostate cancer risk loci, PSA levels, disease aggressiveness and disease-specific mortality.Semantic proximity Read ↗

Does genotyping of risk-associated single nucleotide polymorphisms improve patient selection for prostate biopsy when combined with a prostate cancer risk calculator?Semantic proximity Read ↗

The Stockholm3 blood-test predicts clinically-significant cancer on biopsy: independent validation in a multi-center community cohort.Semantic proximity Read ↗

Prostate cancer screening in men aged 50-69 years (STHLM3): a prospective population-based diagnostic study.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.